Table 1.
Comparisons of BTC PDO collections
| Collections | BTC PDO models |
Tumor types |
Characterizations |
Drug screening |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Success rate (%) | iCCA | eCCA | GB | Others | Histopathologic | Genomic | Transcriptomic | Drugs | Prediction model | |
| Broutier et al.5 | 8 | – | 3 | – | – | 5 | H&E, HepPar-1, EpCAM | WES | RNA-seq | 29 drugs including cisplatin, 5-FU, doxorubicin, and gemcitabine | – |
| Lee et al.6 | 16 | 69.5 | 16 | – | – | – | H&E, CK19, SOX9, PD-L1 | WES | RNA-seq | gemcitabine and cisplatin | – |
| Saito et al.7 | 6 | 33.3 | 3 | – | 1 | 2 | H&E, CK7, MUC1 | WES | microarray | 339 compounds, including antimicrotubule agents, mitomycin C, and aclarubicin | – |
| Kinoshita et al.8 | 60 | 88.2 | 5 | 49 | 1 | 5 | H&E, CK7, HepPar-1 | TP53, KRAS | – | – | – |
| Ren et al.1 | 61 | 74.4 | 44 | 13 | 4 | – | H&E, CK19, CK7 | WES | RNA-seq | gemcitabine, 5-FU, cisplatin, SN-38, oxaliplatin, mitomycin C, paclitaxel | yes, with the NB and SVM models |
Abbreviations: BTC, biliary tract cancer; PDO, patient-derived organoid; iCCA, intrahepatic cholangiocarcinoma; eCCA, extrahepatic cholangiocarcinoma; GB, gallbladder cancer; H&E, hematoxylin and eosin staining; HepPar-1, hepatocyte paraffin-1; EpCAM, epithelial cell adhesion molecule; CK19, cytokeratin 19; SOX9, SRY-box transcription factor 9; PD-L1, programmed death-ligand 1; CK7, cytokeratin 7; MUC1, Mucin 1; TP53, tumor protein p53; KRAS, Kirsten rat sarcoma viral oncogene homolog; WES, whole-exome sequencing; 5-FU, 5-Fluorouracil; NB, naive Bayes; SVM, support vector machine.